top of page
  • Completed

NCT00574288: Phase 1/2: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma - GEN501 study

Updated: Mar 28, 2022

GEN501 study

GEN501 STUDY DARA

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma


Establishment of safety profile of HuMax-CD38 when given as monotherapy in participants with multiple myeloma relapsed from or refractory to at least 2 different cytoreductive therapies and without further established treatment options.


Multiple Locations

International Study


ClinicalTrials.gov Identifier: NCT00574288


 
 

Publications:


Lancet Haematol. 2020 Jun;7


N Engl J Med. 2015 Sep 24


Comments


Posts Archive
bottom of page